Pending testing results, page-291

originally posted this in the chart thread but probably better in another thread.

Lots of conspiracy theories floating around but small stocks rising on announcements and then coming down after is par for the course. Then with the next decent announcement all those people that want to make a million bucks in no more then 3 months and bought high and sold low the first time....do it again.
I personally have zero concern over the share price; its the business I am interested in and reading through the last quarterly things continue to look very positive for the business. The share price will follow positively at some point... No idea when that will be.
I just took out key points from the last quarterly to post here in an attempt to reassure those who are getting more nervous with every cent down.

hTERT business

· been some recovery in demand - should provide a lift in revenues in FY2022.

· working with Mirax to initiate a number of evaluations at key reference centres in South Korea.

· progressing with evaluations in Sweden, Greece and Israel.

EXO-NET™

· accelerated commercial development

· potential to embed the tech into the discovery, research and development phases for multiple diagnostics and therapeutic applications - may lead to future licensing agreements

· initial production lots completed in preparation for launch.

· animation and Key Opinion Leader video (be great to see that if anyone knows where to find it).

· established multiple collaborations with leading research institutes to evaluate the RUO EXONET™ product - Initial feedback has supported its multiple advantages over existing exosome technologies

· progressed discussions with several multinational companies to introduce the parties to RUO EXO-NET's

Diagnostics pipelinecommercialisation

· continued to progress early-stage discussions with multiple potential lab partners who could establish the BARD1 pipeline diagnostics as LDTs in the US.

· continued to engage with Payors and Insurers in the US to determine their clinical data requirements for future reimbursement of our diagnostic tests.

RESEARCH ANDDEVELOPMENT (R&D) UPDATE

· made significant progress across all programs during the March quarter.

· using two BARD1 peptides in combination with CA125 levels less than 70 Units/ml provided a sensitivity of 91% and specificity of 50% for detection of ovarian cancer, compared to 27% sensitivity for CA125 alone in this sample group.

· 100% specificity and 100% sensitivity for all stages of ovarian cancer.

· 100% specificity and over 95% sensitivity for detection of all stages of breast cancer.

· Initial feasibility studies to transfer the test from an SPR to an ELISA platform progressed during the period.

· commenced in-house ELISA development program using SubB2M for detection of prostate and pancreatic cancers.

· commenced studies using SubB2M to improve cancer detection in immunohistochemistry (IHC) tissue sections. Early results are encouraging, - expand this work in the next quarter across multiple potential clinical applications.

· prototypes were supplied to researchers at the University of Sydney and University of Queensland for evaluation in studies on cancer-derived exosomes, with positive results to date.

· studies comparing EXO-NET™ with competitor technologies have demonstrated superior performance of EXO-NET™ over the competitors.

· progressed development of customised EXO-NETs for use in the manufacturing of exosomes for therapeutic applications.

· in discussion with two Australian-based companies working in the therapeutic exosome field to assess appropriate applications for customised EXO-NETs in the exosome manufacturing process.

· positive results from its collaboration with Minomic International for detection of pancreatic cancer; and the University of Liverpool’s assay for type 3c diabetes could be used to identify people at high-risk for pancreatic cancer.

· hTERT study could simplify laboratory implementation and speed customer conversion. final report expected by June 2021.

We have to remember that BD1 is trying to solve some very hard problems and this is going to take a long time (as in 1-2 years not weeks), but at the moment, there is every indication that they are continuing to track along nicely as a business.
I would love to buy more but my average is significantly lower than where it is now but for those who want to average down, this seems like as good a time as any.
I did say before in a previous post that my understanding from the business is that the Exonet hard launch will be either monday or wednesday next week at a forum (i just can't remember which dates or forum of the top of my old head). if you don't read any of the business announcements carefully etc; and you bought in high hoping it will go higher in a couple of months...Im approaching BD1 it as an investment and not a lottery ticket, it feels a lot less stressful.